8-KEarnings & ResultsExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Financial Results (Jul 16, 2026)

Filed July 16, 2026For Securities:ABT

Summary

Abbott Laboratories (ABT) has filed an 8-K report detailing its second quarter 2026 financial results, announced on July 16, 2026. The company's press release, furnished as part of this filing, provides key operational and financial performance metrics. A significant aspect of the announcement is Abbott's use of non-GAAP financial measures, which exclude various items such as acquisition-related expenses, restructuring costs, legal reserves, and certain tax adjustments. These adjustments are presented to offer investors a clearer view of the company's ongoing business performance, as assessed internally by management. While Abbott emphasizes that these non-GAAP figures provide useful insights, the report also includes a cautionary note for investors to consider these measures alongside GAAP-prepared financial statements. The filing primarily serves to disseminate the second quarter earnings announcement and includes the press release and related interactive data files.

Key Highlights

  • 1Abbott Laboratories announced its second quarter 2026 financial results on July 16, 2026.
  • 2The 8-K filing includes a press release detailing the company's performance for the quarter.
  • 3Abbott utilizes non-GAAP financial measures in its reporting to provide a clearer view of ongoing business performance.
  • 4Non-GAAP measures exclude items such as acquisition costs, legal reserves, restructuring actions, and certain tax adjustments.
  • 5The company's management believes these non-GAAP measures are useful for evaluating operational results.
  • 6Investors are advised to consider non-GAAP measures in conjunction with, and not as a substitute for, GAAP financial measures.
  • 7The filing contains Exhibit 99.1 (Press Release) and the Cover Page Interactive Data File.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially announce and provide access to Abbott Laboratories' financial results for the second quarter of 2026, as detailed in their press release dated July 16, 2026.

Non-GAAP financial measures are financial metrics that exclude certain items from GAAP (Generally Accepted Accounting Principles) net earnings. Abbott uses them to adjust for unusual or unpredictable factors like acquisition-related expenses, legal reserves, and tax adjustments, aiming to provide investors with a clearer picture of the company's underlying, ongoing operational performance as viewed by management.

No, investors are cautioned by Abbott Laboratories to consider these non-GAAP financial measures in addition to, and not as a substitute for, the financial measures prepared in accordance with GAAP. The GAAP figures provide the standardized and audited view of the company's financial health.

Abbott's non-GAAP measures exclude a range of items including expenses related to acquisitions, legal reserves, stock-based compensation acceleration due to acquisitions, restructuring actions, certain regulatory costs, adjustments for prior non-cash tax benefits, tax benefits from specified items, tax settlements from prior years, and excess tax benefits from share-based compensation. Intangible amortization expense is also excluded.